RxDoctor Payments Data

Joshua Ivker, MD

Internal Medicine · Birmingham, ALNPI 1639118409

Payments from drug & device makers

$9,575in general payments, 2019–2025

Across 623 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$930
  • AbbVie$924
  • Lilly USA, LLC$904
  • Novo Nordisk$889
  • Amgen$680
  • Gilead$571
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$9,561100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,575 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$74,894
Medicare patients
162
Services billed
2,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$88,858
MounjaroTirzepatide76$78,820
FarxigaDapagliflozin Propanediol65$74,482
EliquisApixaban42$39,473
RybelsusSemaglutide17$37,695
JardianceEmpagliflozin22$34,487
Janumet XrSitagliptin Phos/Metformin Hcl39$32,632
JanuviaSitagliptin Phosphate23$29,210
RexultiBrexpiprazole12$16,935
LinzessLinaclotide29$16,505
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,241
MyrbetriqMirabegron23$12,472
Repatha SyringeEvolocumab12$6,445
Candesartan Cilexetil59$6,303
Testosterone31$5,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$889$126,55376 claims
Lilly USA, LLCMounjaro$904$78,82076 claims
AstraZenecaFarxiga$123$74,48265 claims
MerckJanumet Xr, Januvia$178$61,84262 claims
PfizerEliquis$930$39,47342 claims
Boehringer IngelheimJardiance$182$34,48722 claims
AbbVieLinzess, Synthroid$924$20,07271 claims
Otsuka America Pharmaceutical, Inc.Rexulti$52$16,93512 claims
GSKTrelegy Ellipta$376$14,24115 claims
Astellas Pharma US IncMyrbetriq$233$12,47223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →